Asthma is a complex disease with both genetic and environmental components. The interaction between genetic predisposition and environmental factors is likely to have an important role in the etiology and prognosis of the disease. However, only few studies have addressed gene--environment interactions in asthma ([@b7-ehp-117-1919]; [@b40-ehp-117-1919]; [@b60-ehp-117-1919]).

Air pollution contributes to the development of asthma ([@b5-ehp-117-1919]; [@b21-ehp-117-1919]; [@b29-ehp-117-1919]; [@b41-ehp-117-1919]; [@b43-ehp-117-1919]) and asthma exacerbations ([@b13-ehp-117-1919]; [@b28-ehp-117-1919]; [@b36-ehp-117-1919]; [@b45-ehp-117-1919]). Traffic-related pollutants such as particulate matter, nitrogen dioxide, and ozone are strong oxidants ([@b13-ehp-117-1919]), leading to the production of reactive oxygen species (ROS). Oxidative stress triggers the inflammatory response and cytokine production ([@b33-ehp-117-1919]; [@b45-ehp-117-1919]). It is plausible that genetic variants involved in inflammation and protection against ROS may influence the response to air pollutants. Polymorphisms in oxidative stress genes NAD(P)H:quinine oxidoreductase \[*NQO1*, GeneID 1728 ([@b18-ehp-117-1919])\] and gluthatione *S*-transferases M1 \[*GSTM1*, GeneID 2944 ([@b18-ehp-117-1919])\] and P1 \[*GSTP1*, GeneID 2950 ([@b18-ehp-117-1919])\] have been associated with a decrease on pulmonary function ([@b3-ehp-117-1919]; [@b50-ehp-117-1919]; [@b61-ehp-117-1919]) and with increased allergic response ([@b23-ehp-117-1919], [@b22-ehp-117-1919]), respiratory symptoms, and asthma ([@b14-ehp-117-1919]; [@b37-ehp-117-1919]; [@b38-ehp-117-1919]; [@b49-ehp-117-1919]) in response to air pollutants, including O~3~ and diesel exhaust particles (DEP). Variants in the proinflammatory cytokine gene tumor necrosis factor α \[*TNFA*, GeneID 7124 ([@b18-ehp-117-1919])\] have been linked to decrease in pulmonary function ([@b58-ehp-117-1919]; [@b61-ehp-117-1919]) and asthma and wheezing ([@b38-ehp-117-1919]) in relation to O~3~ and sulfur dioxide exposure. A recent study using nitrogen oxides (NO~x~) as an indicator for local traffic air pollution has reported interaction effects between *GSTP1* polymorphisms and NO~x~ on allergic sensitization to common allergens in children at 4 years of age. This interaction was more pronounced in carriers of *TNFA* −308 GA or AA genotype ([@b42-ehp-117-1919]). Toll-like receptor 4 \[*TLR4*, GeneID 7099 ([@b18-ehp-117-1919])\], implicated in innate immunity and endotoxin responsiveness, is also a candidate to be involved in air pollution susceptibility ([@b48-ehp-117-1919]; [@b52-ehp-117-1919]; [@b60-ehp-117-1919]). In mouse models, lung hyperpermeability induced by O~3~ has been linked to the chromosome region containing the *TLR4* gene ([@b35-ehp-117-1919], [@b34-ehp-117-1919]). Another plausible candidate gene to modify the effects of air pollution is adrenergic receptor β2 \[*ADRB2*, GeneID 154 ([@b18-ehp-117-1919])\]. It has been shown that polymorphisms in this gene interact with environmental tobacco smoke in children ([@b55-ehp-117-1919]; [@b62-ehp-117-1919]) and cigarette smoke in adults ([@b32-ehp-117-1919]; [@b39-ehp-117-1919]; [@b56-ehp-117-1919]). However, a previous study evaluating the combined effects of air pollutants and *ADRB2* in children did not report significant findings ([@b42-ehp-117-1919]).

To date, evidence for gene--air pollution interactions on asthma have been reported only in children ([@b42-ehp-117-1919]; [@b60-ehp-117-1919]). Susceptibility to air pollution in early life may biologically differ from adulthood ([@b51-ehp-117-1919]). Previous analysis on the European Community Respiratory Health Survey (ECRHS) reported that traffic-related pollution (using estimates of modeled NO~2~ exposure) was positively associated with new-onset asthma in adults ([@b29-ehp-117-1919]). The aim of the present study was to identify interactions between genes and traffic-related pollution on asthma incidence and prevalence in a large population-based cohort (ECRHS) of adults. For this purpose, we evaluated previously reported candidate genes that have a role in oxidative stress {*GSTM1*, glutathione *S*-transferase T1 \[*GSTT1*, GeneID 2952 ([@b18-ehp-117-1919])\], *GSTP1*, and *NQO1*}, inflammatory response (*TNFA*), innate immunity (*TLR4*), and airway reactivity (*ADRB2*).

Materials and Methods
=====================

Study population
----------------

The methodology of ECRHS has been described elsewhere ([@b6-ehp-117-1919]; [@b16-ehp-117-1919]). Briefly, the ECRHS is a random population-based multicenter cohort of subjects 20--44 years of age at the time of recruitment (1990; ECRHS I) and then followed approximately 10 years later in ECRHS II (median length of follow-up, 8.9 years). In a first step of ECRHS I, random recruited subjects were contacted to complete a short questionnaire on respiratory symptoms. In a second step, a 20% random sample of participants was recontacted, completed a long questionnaire, and underwent some exams. A complementary sample of subjects with asthma symptoms at recruitment was also included in the study. Ethical approval was obtained for each center from the appropriate institutional ethics committee, and written consent was obtained from each participant.

For ECRHS II, modeled NO~2~ concentrations were assigned to a total of 5,470 participants in the 20 centers for which modeled air pollution was available. Genotyping was performed in 5,065 individuals from 19 centers, for which NO~2~ was measured for 2,920 participants in 13 centers: Sweden (Umeå and Uppsala), United Kingdom (Ipswich and Norwich), Spain (Albacete, Barcelona, Huelva, Galdakao, and Oviedo), Germany (Erfurt), France (Paris and Grenoble), and Belgium (Antwerp). For the present analysis, we excluded subjects from the symptomatic sample who did not report asthma in ECRHS II, leading to a final sample size of 2,577. No major differences were observed between the complete sample with estimated NO~2~, the subsample with DNA, and the subsample with both DNA and NO~2~ \[see Supplemental Material, Table 1 (doi:10.1289/ehp.0900589.S1 via <http://dx.doi.org>)\].

Subjects included in our analysis could be considered as mainly of European--Caucasian origin. The prevalence of asthma was based on a positive response to either of two questions in ECRHS II: attack of asthma during the last 12 months or current use of asthma medication. New-onset (incident) of asthma was defined as reporting asthma (either attack of asthma in preceding 12 months or current medication for asthma) in ECRHS II (follow-up) excluding people who reported asthma (same definition as above) or a history of asthma in ECRHS I (baseline). Persistent asthma was defined as reporting asthma (either attack of asthma in preceding 12 months or current medication for asthma) in both surveys.

We evaluated the robustness of our results with other definitions of asthma: ever asthma, defined as a positive response to "have you ever had asthma?" and physician-diagnosed asthma, defined as a positive response to "have you ever had asthma diagnosed by a doctor?" Participants also underwent a bronchial challenge with methacholine chloride administered by Mefar aerosol dosimeters (Mefar, Bovezzo, Italy). Bronchial hyperresponsiveness was defined as a 20% fall in forced expiratory volume in 1 sec (FEV~1~) from the highest FEV~1~ postdiluent during methacholine challenge with an accumulated dose of 1 mg ([@b6-ehp-117-1919]; [@b10-ehp-117-1919]). Specific IgE levels to house dust mite, cat, timothy grass, and *Cladosporium herbarum* fungus were measured with the Pharmacia CAP system (Pharmacia Diagnostics, Uppsala, Sweden). Atopy was defined as sensitization (IgE levels \> 0.35 kU/L) to any allergen.

Modeled NO~2~ concentrations
----------------------------

NO~2~ has been widely used as a marker of local traffic-related air pollution ([@b17-ehp-117-1919]; [@b19-ehp-117-1919]; [@b29-ehp-117-1919]; [@b43-ehp-117-1919]; [@b44-ehp-117-1919]). NO~2~ measurements substantially differ within cities because they capture differences in exposure due to different proximities to traffic arteries. Details on modeling of NO~2~ concentrations are described in the Supplemental Material (doi:10.1289/ehp.0900589.S1). Briefly, as part of the Air Pollution Modelling for Support to Policy on Health and Environmental Risk in Europe project ([@b1-ehp-117-1919]), 1-km- resolution emission maps were developed. The NO~x~ emission map was used as the basis for modeling NO~2~ concentrations using focal sum techniques in a global information system model. The NO~2~ at the place of residence for each subject was then obtained by intersecting the point locations of their residence with the air pollution map.

DNA extraction and genotype characterization
--------------------------------------------

Polymorphisms of the genes *GSTM1*, *GSTT1*, and *GSTP1* were selected according to functional evidence from existing literature. For the genes *NQO1*, *TNFA*, *TLR4*, and *ADRB2*, we selected tag single-nucleotide polymorphisms (SNPs) in the gene region, 10 kb upstream from the 5′ untranslated region (UTR), and 10 kb downstream from 3′ UTR. Polymorphisms are listed in [Table 1](#t1-ehp-117-1919){ref-type="table"}.

DNA was extracted from blood cells for samples using a commercially available kit (Puregene, Gentra Inc., MN, USA). The DNA bank was built and maintained at Helmholtz Zentrum München in Germany. Genotyping was performed at the Centre for Genomic Regulation in the Barcelona Node of the [@b9-ehp-117-1919] in Spain. *GSTM1* and *GSTT1* genotypes were determined using polymerase chain reaction method and *GSTP1* polymorphism by specific pyrosequencing assay. Genotyping for *NQO1*, *TNFA*, and *TLR4* polymorphisms was performed using the SNPlex platform (Applied Biosystems, Foster City, CA, USA). The average genotyping rate was 98%.

Statistical analysis
--------------------

The statistical analyses were performed using logistic regression implemented in the SNPassoc (version 1.5) ([@b24-ehp-117-1919]) package in R (version 2.6.1; R Foundation for Statistical Computing, Vienna, Austria). Generalized additive models (GAMs) were used to evaluate dose--response relationships with NO~2~. Logistic models and GAMs were adjusted for center, sex, age, environmental tobacco smoke, and smoking status. Multiplicative interactions were assessed using likelihood-ratio test comparing models with additive term and interaction term. Heterogeneity was evaluated using the Mantel--Haenszel method under fixed-effects model with the R library rmeta package (version 2.14). Logistic mixed-effects models allowed the evaluation of a random effect of the variable center. These models were also adjusted for the previously described covariates.

We tested deviations of genotype frequencies from Hardy--Weinberg equilibrium (HWE) ([@b57-ehp-117-1919]) in the randomly selected population. To check the independence of the polymorphisms, we estimated the correlation (*R*^2^) and linkage disequilibrium coefficient (*D*′). Haplotypes were estimated using the haplo.em function from the haplo.stats package (version 1.3.8) ([@b53-ehp-117-1919]). Population stratification was assessed with the analysis of 26 unlinked markers \[see Supplemental Material, Table 2 (doi:10.1289/ehp.0900589.S1)\] using two different methods. First, the genomic control approach ([@b15-ehp-117-1919]) showed a minimal effect \[inflation factor (λ) = 1.06\]. Second, principal component analysis using the EIGENSTRAT method (version 1.01) ([@b47-ehp-117-1919]) showed no evidence of population stratification \[see Supplemental Material, Figure 1 (doi:10.1289/ehp.0900589.S1)\].

Additional information on material and methods can be found in the Supplemental Material (doi:10.1289/ehp.0900589.S1).

Results
=======

[Table 2](#t2-ehp-117-1919){ref-type="table"} lists population characteristics. The prevalence of current asthma in this sample was 12.7% (*n* = 327). Compared with subjects without asthma, asthmatics more often were women, were younger, reported less smoking, and had lower percentage of predicted lung function. Distribution of NO~2~ was similar to the previously reported for the whole population ([@b29-ehp-117-1919]) \[see Supplemental Material, Table 3 (doi:10.1289/ehp.0900589.S1)\]. The multivariate analysis of NO~2~ and prevalence of asthma indicates a small but not significant increase in asthma for each 10-μg/m^3^ increase in NO~2~ \[odds ratio (OR) = 1.19; 95% confidence interval (CI), 0.97--1.47\]. We observed departure from the HWE for *GSTP1* rs16951 (*p* \< 0.01). Allele distribution by center was heterogeneous for *TNFA* rs2844484 and *TNFA* rs909253 variants (*p* \< 0.01).

For each genetic polymorphism, we evaluated the association between NO~2~ (per 10-μg/m^3^ increase) and asthma prevalence separately for carriers of the minor allele (either homozygous or heterozygous) and for the subjects homozygous for the major allele ([Table 1](#t1-ehp-117-1919){ref-type="table"}). We found no statistically significant associations between NO~2~ and asthma for any of the genotypes of *GSTM1*, *GSTT1*, *GSTP1*, *TLR4*, and *ADRB2* genes. The association between prevalence of asthma and NO~2~ was significant for subjects homozygous for the major allele of *NQO1* rs2917666 (OR = 1.54; 95% CI, 1.10--2.24) and for *TNFA* rs2844484 (OR = 2.02; 95% CI, 1.30--3.27). A test for interaction between these polymorphisms and NO~2~ was significant only for *NQO1* rs2917666 (*p*-value for interaction = 0.02). Analysis using GAMs ([Figure 1](#f1-ehp-117-1919){ref-type="fig"}) indicated a significant linear increase in prevalence for homozygotes of the most prevalent alleles in *NQO1* rs2917666 (*p* = 0.02) and no increase for the G/C and G/G genotypes.

We further performed the haplotype analysis for the three SNPs of *NQO1* (rs10517, rs1800566, and rs2917666) in relation to NO~2~ exposure and prevalence of asthma ([Table 3](#t3-ehp-117-1919){ref-type="table"}). In this analysis, we provide estimates for exposure among subjects within combinations of SNPs. Linkage disequilibrium was weak between some of the *NQO1* SNPs (*D*′ = 0.97, *r*^2^ = 0.03, and *p* \< 0.01 between rs10517 and rs1800566; *D*′ = 0.86, *r*^2^ = 0.21, and *p* \< 0.01 between rs10517 and rs2917666; *D*′ = 0.99, *r*^2^ = 0.53, and *p* \< 0.01 between rs1800566 and rs2917666). The association between asthma prevalence and NO~2~ was significant for the most prevalent haplotype, composed of the three major alleles of each SNP (OR = 1.23; 95% CI, 1.03--1.48). This was the only haplotype containing the C allele of rs2917666, which showed a significant interaction with NO~2~ in the single SNP analysis. We observed no significant associations among carriers of the other haplotypes ([Table 3](#t3-ehp-117-1919){ref-type="table"}).

We also analyzed longitudinal data to evaluate the effect of NO~2~ on new-onset asthma. We observed a significant association between new-onset asthma and NO~2~ levels for the 120 subjects who developed asthma during the follow-up period (OR = 1.52; 95% CI, 1.09--2.16). Subjects homozygous for the *NQO1* rs291766 C allele were at greater risk (*p*-value for interaction = 0.04) for developing asthma (OR = 2.02; 95% CI, 1.16--3.73) compared with those with CG/GG genotypes (OR = 1.26; 95% CI, 0.83--1.99).

We restricted the analysis to those subjects who lived in the same home during follow-up (*n* = 1,348) to reduce exposure misclassification. Compared with subjects who changed homes, this group had an increased risk for main effects of exposure to NO~2~ on asthma prevalence (movers: OR = 1.64; 95% CI, 1.08--2.53; nonmovers: OR = 1.02; 95% CI, 0.80--1.31; *p*-value for interaction = 0.03), whereas the effect on new-onset asthma was not different between movers and nonmovers (movers: OR = 1.48; 95% CI, 0.83--2.74; nonmovers: OR =1.59; 95% CI, 1.05--2.52; *p*-value for interaction = 0.81). CC carriers of *NQO1* rs2917666 living in the same home during follow-up had an increased risk for prevalence (OR = 2.42; 95% CI, 1.19--5.24) and new-onset asthma (OR = 2.89; 95% CI, 1.02--9.46).

In a sensitivity analysis, we also evaluated our findings of interaction between *NQO1* rs2917666 and NO~2~ for other asthma definitions and asthma-related phenotypes \[see Supplemental Material, Table 4 (doi:10.1289/ehp.0900589.S1)\]. Interaction was significant for ever asthma (*p* = 0.006), physician-diagnosed asthma (*p* = 0.01), and asthmatics showing bronchial hyperresponsiveness (*p* = 0.02), whereas interactions were not significant for persistent asthma (*p* = 0.12) or atopy (*p* = 0.46). Stratification by atopic status showed that interaction between NO~2~ and *NQO1* rs2917666 was more pronounced among nonatopic carriers of *NQO1* rs2917666 C/C (OR = 2.38; 95% CI, 1.13--5.68; *p*-value for interaction = 0.01) compared with atopic subjects (OR = 1.24; 95% CI, 0.84--1.91; *p*-value for interaction = 0.45).

When stratified by sex \[see Supplemental Material, Table 5 (doi:10.1289/ehp.0900589.S1)\], interaction between NO~2~ and rs2917666 was significant only among females (C/C: OR = 1.81; 95% CI, 1.13--3.09; *p*-value for interaction = 0.03) and not in males (C/C: OR = 1.39; 95% CI, 0.82--2.46; *p*-value for interaction = 0.24). However, heterogeneity by gender was not significant (*p* = 0.71). We observed no significant differences in the effect of NO~2~ and *NQO1* rs2917666 on current asthma by center (*p*-value for heterogeneity = 0.51). In addition, after including the random effects of center in a generalized mixed model, the interaction of NO~2~ and *NQO1* rs2917666 was still significant for the prevalence of asthma (*p*-value for interaction = 0.02). Heterogeneity was not significant among different socioeconomic strata based on occupation (*p*-value for heterogeneity = 0.28). The exclusion of non-randomly selected symptomatic subjects in the second step of ECRHS I did not modify the effects observed in the whole sample (*p*-value for heterogeneity = 0.36)

Discussion
==========

We evaluated the effect of genes involved in oxidative stress pathways (*GSTM1*, *GSTT1*, *GSTP1*, and *NQO1*), inflammatory response (*TNFA*), immunologic response (*TLR4*), and airway reactivity (*ADRB2*) on the association of traffic-related air pollution (using estimates of modeled NO~2~ exposure) and adult asthma in a large, multicenter population-based cohort. We observed stronger associations between NO~2~ concentrations and both prevalent and new-onset asthma among subjects homozygous for the most common allele of *NQO1* compared with carriers of *NQO1* variants. Although several studies have evaluated similar gene--environment interactions in children ([@b3-ehp-117-1919]; [@b14-ehp-117-1919]; [@b37-ehp-117-1919]; [@b38-ehp-117-1919]; [@b42-ehp-117-1919]; [@b50-ehp-117-1919], [@b49-ehp-117-1919]) and in experimental settings in adults ([@b12-ehp-117-1919]; [@b23-ehp-117-1919], [@b22-ehp-117-1919]; [@b58-ehp-117-1919]; [@b61-ehp-117-1919]), this is the first study examining the interaction of genetic variation and long-term air pollution on asthma in adults.

Similar to other studies, we used NO~2~ level as a marker of traffic-related air pollution ([@b17-ehp-117-1919]; [@b19-ehp-117-1919]; [@b29-ehp-117-1919]; [@b42-ehp-117-1919]; [@b43-ehp-117-1919]; [@b44-ehp-117-1919]). Thus, the observed associations and interactions may be mediated by other ambient air pollutants, which are highly spatially correlated with NO~2~. However, NO~2~ is a strong oxidant per se, with a range of well-known adverse effects ([@b19-ehp-117-1919]; [@b31-ehp-117-1919]), and NO~2~ either alone or combined with other pollutants may contribute to the observed effects ([@b19-ehp-117-1919]).

In our study, we found a nonsignificant reduction of the NO~2~ effects among carriers of at least one *NQO1* Ser187 allele. The polymorphism that was associated with the most significant *p*-value in our study (rs2917666) is not known to be functional but is located in the 5′ upstream region of the gene. This region contains elements essential for the expression and induction of *NQO1*, such as the antioxidant response element that is required for *NQO1* transcription in response to oxidative stress ([@b30-ehp-117-1919]; [@b46-ehp-117-1919]). The three SNPs in the *NQO1* gene were in relatively weak linkage disequilibrium with the highest *r*^2^ (0.53) found for the functional Pro187Ser (rs1800566) and rs2917666. Furthermore, the association between asthma and modeled NO~2~ was significant for the most prevalent haplotype that contained the C allele of the rs2917666, which showed a significant interaction with NO~2~ in the single SNP analysis. A few studies have evaluated the role of *NQO1* in relation to exposure to O~3~ \[reviewed by [@b60-ehp-117-1919]\] and have shown that the Pro187Ser (rs1800566) polymorphism was protective in response to O~3~ when *GSTM1* was present ([@b3-ehp-117-1919]; [@b12-ehp-117-1919]; [@b14-ehp-117-1919]). Susceptibility variants on oxidative stress genes *GSTM1* and *GSTP1* have been associated with an increased effect of air pollution and specific pollutants ([@b23-ehp-117-1919]; [@b37-ehp-117-1919]; [@b38-ehp-117-1919]; [@b42-ehp-117-1919]; [@b50-ehp-117-1919], [@b49-ehp-117-1919]). In this study, we did not observe significant associations of *GSTM1* or *GSTP1* polymorphisms with asthma either alone or in combination with *NQO1* SNPs. Lack of consistence with previous analyses could be related to the heterogeneity of effects in adults compared with children ([@b51-ehp-117-1919]).

Our findings on *NQO1* reinforce the role of antioxidant system in response to air pollution ([@b33-ehp-117-1919]; [@b48-ehp-117-1919]). An *in vitro* approach proposed a hierarchical model to explain the dose-dependent response to oxidant chemicals in DEP ([@b59-ehp-117-1919]) that will probably extend to gaseous pollutants like NO~2~ ([@b52-ehp-117-1919]). With low exposure, the formation of ROS activates the transcription of genes involved in antioxidant responses, such as phase II enzymes (e.g., *NQO1* and GST genes). Higher exposure activates the transcription of nuclear factor-κB and activator protein-1, resulting in increased expression of proinflammatory cytokines (e.g., TNF-α), leading to additional generation of ROS ([@b48-ehp-117-1919]; [@b52-ehp-117-1919]).

The ECRHS is a large population-based international cohort that overcomes limitations of studies done in selected populations. The main limitations of this analysis include limited statistical power to detect interactions, some exposure misclassification, and heterogeneity and potential confounding concerning environmental exposures and genetic variation.

Statistical power to detect interactions was relatively low ([@b20-ehp-117-1919]). False-positive results have been shown to be frequent in studies on genetic variation and gene--environment interactions ([@b11-ehp-117-1919]), and for these reason these results should be interpreted with caution. In this study we did not perform correction for multiple comparisons. However, traditional methods based on Bonferroni are overconservative because polymorphisms within a gene are not completely independent due to linkage disequilibrium. In addition, this correction may be acceptable when searching for significant associations without preestablished hypotheses, but we selected genes in this analysis on the basis of strong prior evidence.

Strengths and limitations of the NO~2~ exposure assessment have been discussed previously ([@b29-ehp-117-1919]). The individual assignment of exposure to NO~2~ should result in a reduction of exposure misclassification. We evaluated NO~2~ exposure by geocoding home addresses of ECRHS participants and assigned ambient modeled NO~2~ concentration derived from the APMoSPHERE map to each subject. The year of modeled NO~2~ (2001) was concordant with the years of the administration of the ECRHS II questionnaire (1999--2002). However, the spatial scale of the APMoSPHERE model was relatively broad (1 × 1 km), and the model did not include monitors placed close to traffic. Thus, spatial and temporal contrasts in exposure due to very local emissions and dispersion patterns, such as those occurring in street canyons are unlikely to be captured. NO~2~ does also capture part of that space but as a secondary gas is certainly more homogeneously distributed than, for example, ultrafine tail pipe particles. The misclassification is random in nature so, if anything, some bias toward the null may be expected. If those local peak concentrations were particularly relevant sources of exposure to oxidants, the APMoSPHERE-based results would likely underestimate true effects and interactions.

Because of the lack of repeated measurements during follow-up, exposure was assigned only to residences in ECRHS II. Although levels of air pollution did not remain constant during the follow-up period, the ranking in the spatial distribution of traffic-related pollutants is likely to remain similar. Exposure misclassification is thus particularly large among those who moved after ECRHS I, possibly explaining the smaller effects observed among movers ([@b2-ehp-117-1919]; [@b25-ehp-117-1919]).

Levels of air pollution and prevalence of asthma varied substantially across centers in ECRHS, showing a south--north gradient ([@b26-ehp-117-1919]; [@b29-ehp-117-1919]; [@b54-ehp-117-1919]). Median levels of modeled NO~2~ varied from 12 μg/m^3^ in Umeå to more than 50 μg/m^3^ in Barcelona and Paris ([@b29-ehp-117-1919]). Variables correlated with center, such as pollution composition, climatic factors, and diet, determine the individual response to air pollution ([@b13-ehp-117-1919]). All results were adjusted by center, and random-effects meta-analysis suggested that NO~2~ estimates and interactions with the genes were not center specific, although we acknowledge the limited power to detect this heterogeneity. In addition, recent analyses of population stratification among Europeans found correspondence between genetic variation and geographic distances, although levels of genetic diversity were low ([@b27-ehp-117-1919]). Previous analyses in the ECRHS have shown little evidence of population stratification ([@b8-ehp-117-1919]). However, this was based on an insufficient set of markers.

An important source of NO~2~ exposure in the general population originates from the use of gas cookers ([@b13-ehp-117-1919]). Several studies reported the association of indoor exposures with NO~2~ outcomes and respiratory or allergic outcomes ([@b4-ehp-117-1919]). In our data, outdoor NO~2~ was not correlated with gas cooking, and adjustment for cooking with gas did not affect the observed effects of outdoor NO~2~ and its interaction with the *NQO1* polymorphism.

Differences were observed by sex, with females showing an increase in risk. However, the sample sizes of specific strata are smaller than the total population, and interpretation of these results should be done with caution. Our findings, if corroborated by others, may have significant public health implications because we identified a large group of susceptible subjects defined by the genetic makeup for whom the effect of modeled NO~2~-related air pollution on asthma was substantial. The affected subgroup was large, with a 46% prevalence of the C/C genotype for *NQO1* rs2917666. Moreover, the number of people exposed to traffic-related pollution on a regular basis is large and as a consequence the burden of asthma related to ambient air pollution may be large not only in children, as previously documented, but also in adults.

Conclusions
===========

Findings from this study suggest that genetic polymorphisms in the *NQO1* gene are associated with susceptibility to asthma in adults among those exposed to traffic-related air pollution. This result points to the importance of antioxidant pathways in the effects of air pollution on asthma.
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Supplemental Material is available online (doi:10.1289/ehp.0900589.S1 via <http://dx.doi.org/>).
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Association of NO~2~ (per 10 μg/m^3^) and asthma prevalence according to polymorphisms in ECRHS II.

  Gene      Polymorphism   Minor allele frequency   Coding change       Variant   No. asthmatics (%)   OR (95% CI)
  --------- -------------- ------------------------ ------------------- --------- -------------------- -------------------
  *GSTM1*   Deletion       49.0                     ---                 Present   134 (12.0)           1.10 (0.8--1.54)
                                                                        Null      152 (13.2)           1.06 (0.78--1.46)
                                                                                                       
  *GSTT1*   Deletion       20.0                     ---                 Present   217 (12.0)           0.98 (0.78--1.26)
                                                                        Null      69 (15.2)            1.69 (0.97--3.07)
                                                                                                       
  *GSTP1*   rs1695         32.0                     Exon 5 Ile105Val    A/A       104 (11.2)           1.34 (0.97--1.93)
                                                                        A/G+G/G   211 (14.1)           1.10 (0.84--1.46)
                                                                                                       
  *NQO1*    rs10517        11.9                     3′ UTR region       C/C       131 (14.1)           1.20 (0.96--1.53)
                                                                        C/T+T/T   193 (11.8)           1.11 (0.71--1.82)
                                                                                                       
  *NQO1*    rs1800566      20.2                     Exon 6 Pro187Ser    C/C       222 (12.7)           1.36 (1.03--1.84)
                                                                        C/T+T/T   102 (12.5)           1.06 (0.79--1.45)
                                                                                                       
  *NQO1*    rs2917666      32.2                     3′ downstream       C/C       163 (12.8)           1.54 (1.10--2.24)
                                                                        C/G+G/G   164 (12.7)           1.01 (0.79--1.33)
                                                                                                       
  *TLR4*    rs10759930     40.1                     5′ upstream         C/C       143 (13.5)           1.13 (0.80--1.65)
                                                                        C/T+T/T   163 (12.3)           1.21 (0.95--1.58)
                                                                                                       
  *TLR4*    rs11536889     14.3                     3′ UTR region       G/G       255 (12.9)           1.22 (0.96--1.58)
                                                                        G/C+C/C   72 (12.3)            1.24 (0.83--1.98)
                                                                                                       
  *TLR4*    rs1554973      23.7                     3′ downstream       T/T       207 (12.5)           1.19 (0.91--1.58)
                                                                        T/C+C/C   119 (13.0)           1.19 (0.87--1.66)
                                                                                                       
  *TLR4*    rs1927914      32.5                     5′ UTR region       T/T       155 (12.9)           1.20 (0.89--1.65)
                                                                        T/C+C/C   171 (12.5)           1.18 (0.90--1.58)
                                                                                                       
  *TLR4*    rs2737191      27.3                     5′ upstream         A/A       115 (12.4)           1.28 (0.96--1.73)
                                                                        A/G+G/G   212 (13.0)           1.10 (0.82--1.49)
                                                                                                       
  *TNFA*    rs1800629      16.1                     5′ upstream         G/G       207 (12.0)           1.27 (0.97--1.69)
                                                                        G/A+A/A   69 (11.1)            1.22 (0.86--1.80)
                                                                                                       
  *TNFA*    rs2844484      41.2                     5′ upstream         C/C       196 (13.1)           2.02 (1.30--3.27)
                                                                        C/T+T/T   131 (12.2)           1.02 (0.81--1.30)
                                                                                                       
  *TNFA*    rs909253       31.2                     Intron 3 of LTA     A/A       146 (12.4)           1.29 (0.96--1.76)
                                                                        A/G+G/G   180 (13.0)           1.14 (0.86--1.54)
                                                                                                       
  *ADRB2*   rs1042713      38.8                     Exon 1 Arg16Gly     G/G       166 (12.3)           1.03 (0.73--1.50)
                                                                        G/A+A/A   160 (13.2)           1.18 (0.91--1.56)
                                                                                                       
  *ADRB2*   rs1042714      40.0                     Exon 1 Gln27Glu     C/C       197 (12.0)           1.21 (0.88--1.70)
                                                                        C/G+G/G   102 (14.9)           1.20 (0.92--1.60)
                                                                                                       
  *ADRB2*   rs1042718      17.7                     Exon 1 synonymous   C/C       115 (12.3)           1.21 (0.94--1.57)
                                                                        C/A+A/A   212 (12.9)           1.20 (0.79--1.65)
                                                                                                       
  *ADRB2*   rs1042719      30.4                     Exon 1 synonymous   G/G       147 (12.0)           1.23 (0.92--1.68)
                                                                        G/C+C/C   180 (13.4)           1.19 (0.89--1.63)

###### 

Population characteristics at follow-up (ECRHS II) for subjects with both DNA and assigned levels of NO~2~.

                                            All             No asthma       Asthma         *p*-Value
  ----------------------------------------- --------------- --------------- -------------- -----------
  Subjects (no.)                            2,577           2,250           327            ---
  Females \[no. (%)\]                       1,345 (52.2)    1,154 (51.3)    191 (58.4)     0.02
  Age \[years (mean ± SD)\]                 43.03 ± 7.3     43.2 ± 7.2      41.83 ± 7.2    0.001
  Smoking status \[no. (%)\]                                                               
   Never                                    1,130 (44)      969 (43.1)      161 (49.2)     ---
   Former                                   714 (27.8)      624 (27.8)      90 (27.5)      ---
   Current                                  729 (28.3)      653 (29.1)      76 (23.2)      0.05
  Same house during follow-up \[no. (%)\]   1,348 (52.3)    1,192 (53.0)    156 (47.7)     0.08
  Percent predicted FEV~1~ (mean ± SD)      106.81 ± 15.2   108.86 ± 13.9   95.58 ± 18.2   \< 0.001

###### 

Association of NO~2~ per 10-μg/m^3^ increase and asthma prevalence stratified by *NQO1* and haplotypes in ECRHS II.

  Haplotype   Allele   Prevalence   OR (95% CI)   *p*-Value   *p*-Value for interaction          
  ----------- -------- ------------ ------------- ----------- --------------------------- ------ -----------
  1           C        C            C             0.66        1.23 (1.03--1.48)           0.03   Reference
  2           C        T            G             0.21        1.28 (0.90--1.89)           0.20   0.50
  3           T        C            G             0.11        1.11 (0.72--1.81)           0.66   0.73
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